CytomX Therapeutics, Inc. — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Working Capital Components
Total Assets↑+25.7% +$31M
$152M
Current Assets↑+34.1% +$37M
$144M
Cash & Equivalents↓-66.7% -$25M
$13M
ST Investments
—
Receivables↓-35.1% -$1M
$2M
Net PPE↓-47.1% -$1M
$1M
Goodwill↑+0.0% +$0
$949K
Intangibles
—
Total Liabilities↓-56.6% -$68M
$53M
Current Liabilities↓-45.7% -$39M
$47M
Account Payables↑+19.6% +$213K
$1M
Long-Term Debt
—
Stockholders Equity↑+21812.3% +$99M
$99M
Retained Earnings↓-2.9% -$20M
$-712M
Operating Lease ROU Asset↓-58.3% -$5M
$3M
Operating Lease Liability↓-100.0% -$4M
$0
Gross PP&E↓-2.5% -$474K
$18M
Accumulated Depreciation↑+4.2% +$689K
$17M
Contract Liability↓-69.7% -$66M
$28M
Contract Liability (Current)↓-60.0% -$40M
$27M
Contract Liability (Noncurrent)↓-94.1% -$25M
$2M